Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Integra LifeSciences Holdings Corporation stock

Own Integra LifeSciences Holdings Corporation stock in just a few minutes.

Integra LifeSciences Holdings Corporation is a medical devices business based in the US. Integra LifeSciences Holdings Corporation shares (IART) are listed on the NASDAQ and all prices are listed in US Dollars. Integra LifeSciences Holdings Corporation employs 3,700 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Integra LifeSciences Holdings Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IART – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Integra LifeSciences Holdings Corporation share price

Use our graph to track the performance of IART stocks over time.

Integra LifeSciences Holdings Corporation shares at a glance

Information last updated 2021-04-30.
52-week range$42.12 - $77.40
50-day moving average $69.93
200-day moving average $62.82
Wall St. target price$77.45
PE ratio 48.3631
Dividend yield N/A (0%)
Earnings per share (TTM) $1.57

Buy Integra LifeSciences Holdings Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Integra LifeSciences Holdings Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Integra LifeSciences Holdings Corporation under- or over-valued?

Valuing Integra LifeSciences Holdings Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Integra LifeSciences Holdings Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Integra LifeSciences Holdings Corporation's P/E ratio

Integra LifeSciences Holdings Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Integra LifeSciences Holdings Corporation shares trade at around 48x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Integra LifeSciences Holdings Corporation's PEG ratio

Integra LifeSciences Holdings Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1464. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Integra LifeSciences Holdings Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Integra LifeSciences Holdings Corporation's EBITDA

Integra LifeSciences Holdings Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $335.8 million.

The EBITDA is a measure of a Integra LifeSciences Holdings Corporation's overall financial performance and is widely used to measure a its profitability.

Integra LifeSciences Holdings Corporation financials

Revenue TTM $1.4 billion
Operating margin TTM 16.02%
Gross profit TTM $885.6 million
Return on assets TTM 3.97%
Return on equity TTM 9.13%
Profit margin 9.76%
Book value $17.96
Market capitalisation $6.4 billion

TTM: trailing 12 months

Shorting Integra LifeSciences Holdings Corporation shares

There are currently 3.6 million Integra LifeSciences Holdings Corporation shares held short by investors – that's known as Integra LifeSciences Holdings Corporation's "short interest". This figure is 0.4% up from 3.6 million last month.

There are a few different ways that this level of interest in shorting Integra LifeSciences Holdings Corporation shares can be evaluated.

Integra LifeSciences Holdings Corporation's "short interest ratio" (SIR)

Integra LifeSciences Holdings Corporation's "short interest ratio" (SIR) is the quantity of Integra LifeSciences Holdings Corporation shares currently shorted divided by the average quantity of Integra LifeSciences Holdings Corporation shares traded daily (recently around 326063.41681574). Integra LifeSciences Holdings Corporation's SIR currently stands at 11.18. In other words for every 100,000 Integra LifeSciences Holdings Corporation shares traded daily on the market, roughly 11180 shares are currently held short.

However Integra LifeSciences Holdings Corporation's short interest can also be evaluated against the total number of Integra LifeSciences Holdings Corporation shares, or, against the total number of tradable Integra LifeSciences Holdings Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Integra LifeSciences Holdings Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Integra LifeSciences Holdings Corporation shares in existence, roughly 40 shares are currently held short) or 0.0584% of the tradable shares (for every 100,000 tradable Integra LifeSciences Holdings Corporation shares, roughly 58 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Integra LifeSciences Holdings Corporation.

Find out more about how you can short Integra LifeSciences Holdings Corporation stock.

Integra LifeSciences Holdings Corporation share dividends

We're not expecting Integra LifeSciences Holdings Corporation to pay a dividend over the next 12 months.

Have Integra LifeSciences Holdings Corporation's shares ever split?

Integra LifeSciences Holdings Corporation's shares were split on a 2:1 basis on 3 January 2017. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Integra LifeSciences Holdings Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Integra LifeSciences Holdings Corporation shares which in turn could have impacted Integra LifeSciences Holdings Corporation's share price.

Integra LifeSciences Holdings Corporation share price volatility

Over the last 12 months, Integra LifeSciences Holdings Corporation's shares have ranged in value from as little as $42.12 up to $77.4. A popular way to gauge a stock's volatility is its "beta".

IART.US volatility(beta: 1.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Integra LifeSciences Holdings Corporation's is 1.2162. This would suggest that Integra LifeSciences Holdings Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Integra LifeSciences Holdings Corporation overview

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site